{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013837","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.023782+00:00","generated_at":"2026-05-15T08:08:06.265857+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cocrystal Pharma reports 2025 net loss of $8.8M ($0.78/sh); cash $7.7M; norovirus challenge study underway","bullets":["Net loss $8.8M ($0.78/sh) vs $17.5M ($1.72/sh) in 2024; R&D spend down to $5.1M from $12.5M.","Unrestricted cash $7.7M at Dec 31, 2025 vs $9.9M a year earlier; working capital $5.9M.","Phase 1b norovirus challenge study of CDI-988 underway at Emory; first cohort evaluating GII.2 strain.","CDI-988 is first oral antiviral candidate for norovirus; no approved treatments/vaccines exist; $60B global burden.","Influenza CC-42344 Phase 2a completed; efficacy not reported due to trial conduct; plans for additional Phase 2a study."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013837","json":"https://secwatch.observer/filing/0001493152-26-013837.json","markdown":"https://secwatch.observer/filing/0001493152-26-013837.md","text":"https://secwatch.observer/filing/0001493152-26-013837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226013837/0001493152-26-013837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226013837/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:08:06.265857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b45a2ccd2994cda8f0b1294275581a5f68c9fd14","claim":"Cocrystal Pharma, Inc. reported financial results for the year ended December 31, 2025.","evidence_excerpt":"Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the year ended December 31, 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226013837/0001493152-26-013837-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}